New Clinical Guidelines for the Treatment of Brain Tumors Published

September 9, 2021 11:25:38

Researchers from the Medical University of Vienna have published clinical recommendations for the treatment and diagnosis of brain metastases from solid tumors. These joint recommendations include the latest methods for diagnosis, treatment, prevention and follow-up for brain metastases. They were drafted in partnership with experts from the European Society for Medical Oncology and the European Association of Neuro-Oncology.

The experts note that these guidelines are a valuable source of information for physicians and other service providers, as well as patients and their families. The guidelines were published in the “Annals of Oncology” journal.

Brain metastasis is common in cancer patients. For most patients, the objective of brain metastases treatment is to delay or prevent neurological deterioration to help prolong survival and improve the quality of life of patients. Of this number, only a few patients, especially those with small lesions, may experience total recovery.

Matthias Preusser, the lead author of the guidelines and the current president of the European Association of Neuro-Oncology, stated that the researchers had made significant progress in the biological treatment and diagnosis of brain metastases, as well as understanding brain metastases better. Preusser, who is also head of the  division of oncology head under the Department of Internal Medicine at the Medical University of Vienna, explained that the examination of tumor tissues was becoming important in the field of diagnostics as molecular analysis of cerebrospinal fluid or blood samples usually revealed genetic changes. which could be utilized as a basis for choosing targeted treatments.

Anna Berghoff, co-author of the study, explained that modern cancer treatments were personalized, noting that individually targeted immunotherapies and treatments were a therapeutic approach with great potential.

Preusser also explained that in the past few years, distinguishable successes had been achieved in treatment, as response rates were substantially increased in the treatment of brain metastases caused by skin cancer. He then noted that more than 55% of patients suffering from asymptomatic brain metastases of skin cancer could achieve sustained remissions in the brain after undergoing immunotherapy.

In addition to this, response rates above 50% had also been achieved with individualized treatments for brain metastases of breast cancer and lung cancer, particularly when gene amplifications or oncogenic mutations were present in the tumors. Preusser further explains that brain metastases were still one of the most severe situations in oncology. However, he asserted that advances in oncology based off of biological research were leading to better and longer survival for various patients, noting that these successes provided researchers with motivation to carry on with their research.

As brain diagnostics advance through the efforts of companies such as Brain Scientific Inc. (OTCQB: BRSF), it is likely to get easier to catch neurological conditions early when chances of complete healing are higher.

NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.